COMMUNIQUÉS West-GlobeNewswire

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of [...]
Lite Strategy Reports Fiscal 2026 Third Quarter Results
13/05/2026
Lite Strategy Continues to Deliver Recurring Yield on Litecoin Holdings and Advance Share Repurchase Program SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “ [...]
Century Therapeutics Reports First Quarter Financial Results and Business Updates
13/05/2026
CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American [...]
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
13/05/2026
Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnology company [...]
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
13/05/2026
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2 nd half [...]
Amlogenyx Presents Preclinical Data on AM805, a Potentially Transformative Investigational Gene Therapy for Alzheimer’s Disease
13/05/2026
A novel approach using a lysosomal enzyme to prevent and reverse amyloid accumulation inside as well as outside neurons, with greater potency, delivered in a one-time gene therapy The therapeutic strategy has the [...]
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
13/05/2026
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026 Program targets [...]
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
13/05/2026
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL [...]
Pyxis Oncology to Participate in Upcoming Investor Conferences
13/05/2026
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will [...]
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
13/05/2026
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing [...]
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
13/05/2026
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF [...]
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
13/05/2026
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026 Net income increased by over 100 % year-over-year to $ 2. 3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year- [...]
Rectify Pharmaceuticals to Present Preclinical Data on New Dual Targeted ABCB4/BSEP Positive Functional Modulator at EASL 2026
13/05/2026
Data highlight RTY-406's dual ABCB4/BSEP mechanism and marks the first demonstration of proof of mechanism in a non-human primate model that closely mirrors the human hepatobiliary system BOSTON, May 13, 2026 (GLOBE [...]
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
13/05/2026
First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- [...]
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
13/05/2026
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first [...]
Candel Therapeutics to Present at Upcoming Investor Conferences
13/05/2026
NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a [...]
Cannabix Marijuana Breath Test Achieves Major Milestone: Breath Collection Unit Secures UL and CSA Certifications
13/05/2026
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce that its portable Breath Collection [...]
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
13/05/2026
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing [...]

Pages